Latest News and Press Releases

EBT-101 is an in vivo CRISPR-based therapeutic designed to remove HIV proviral DNA from affected cell reservoirs First-in-human study will evaluate the safety and efficacy of EBT-101 in participants...

SAN FRANCISCO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases,...

SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced...

EBT-101 achieves HIV excision without detectable off-target effectsPoster presentation to take place today from 5:30 – 6:30 PM ET SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Excision...

EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIVFirst-in-human trial is now open for enrollment SAN FRANCISCO, Jan. 27, 2022 (GLOBE...

Sara Turken, J.D., as General CounselManish Anand, M.Sc., as Senior Vice President, Regulatory AffairsRobert Gunning, CPA, CGMA, as VP, Controller SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- ...

EBT-101, first-in-human CRISPR-based one-time gene therapy to be evaluated in individuals with HIVInitiation of EBT-101 Phase 1/2 clinical trial expected later this year SAN FRANCISCO, Sept. 15,...

CRISPR-based therapies as a curative approach to HIV infection included in the program for first time.Collaboration with Temple University includes research on EBT-101, a CRISPR-based therapeutic...

SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of...

SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...